专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150017241A1 ORAL FORMULATIONS OF DEFERASIROX 有权
标题翻译： DEFERASIROX的口服制剂
公开(公告)号：US20150017241A1
公开(公告)日：2015-01-15
申请号：US14198872
申请日：2014-03-06
申请人： Indrajit Ghosh , Jia-Ai Zhang
发明人： Indrajit Ghosh , Jia-Ai Zhang
IPC分类号： A61K31/4196 , A61K9/50 , A61K9/20 , A61K9/28
CPC分类号： A61K9/2846 , A61K9/0053 , A61K9/148 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K9/5026 , A61K9/5089 , A61K31/125 , A61K31/4196
摘要： Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
摘要翻译：本发明公开了口服给药的去铁调脂素配方，其在胃液条件下具有减少的释放，并在接近中性pH或中性pH下快速释放。

2. 发明授权

US09283209B2 Oral formulations of deferasirox 有权
标题翻译：地拉西罗的口服制剂
公开(公告)号：US09283209B2
公开(公告)日：2016-03-15
申请号：US14198872
申请日：2014-03-06
申请人： Indrajit Ghosh , Jia-Ai Zhang
发明人： Indrajit Ghosh , Jia-Ai Zhang
IPC分类号： A61K31/41 , A61K9/22 , A61K31/4196 , A61K9/20 , A61K9/28 , A61K9/50
CPC分类号： A61K9/2846 , A61K9/0053 , A61K9/148 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K9/5026 , A61K9/5089 , A61K31/125 , A61K31/4196
摘要： Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
摘要翻译：本发明公开了口服可以使用的地拉西罗配方，其在胃的条件下具有减少的释放，并在接近中性pH或中性pH下快速释放。

3. 发明申请

US20160220493A1 ORAL FORMULATIONS OF DEFERASIROX 审中-公开
公开(公告)号：US20160220493A1
公开(公告)日：2016-08-04
申请号：US15017084
申请日：2016-02-05
申请人： Indrajit Ghosh , Jia-Ai Zhang
发明人： Indrajit Ghosh , Jia-Ai Zhang
IPC分类号： A61K9/28 , A61K31/4196 , A61K9/20 , A61K9/00
CPC分类号： A61K9/2846 , A61K9/0053 , A61K9/148 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K9/5026 , A61K9/5089 , A61K31/125 , A61K31/4196
摘要： Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

4. 发明授权

US08298573B2 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs 有权
标题翻译：稳定无菌可过滤脂质体包封的紫杉烷等抗肿瘤药物
公开(公告)号：US08298573B2
公开(公告)日：2012-10-30
申请号：US11196123
申请日：2005-08-03
申请人： Jia-Ai Zhang , Sydney Ugwu , Lan Ma , Gopal Anyarambhatla , Imran Ahmad
发明人： Jia-Ai Zhang , Sydney Ugwu , Lan Ma , Gopal Anyarambhatla , Imran Ahmad
IPC分类号： A61K9/127 , A61K31/335
CPC分类号： A61K9/127 , A61K9/1272 , A61K9/19 , A61K31/337
摘要： The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.
摘要翻译：本发明提供了包封在脂质体中的一种或多种抗肿瘤药物的制剂，其包括至少除了抗肿瘤药物之外的脂质部分，其中该组合物在室温下在水溶液中是稳定的。

5. 发明申请

US20060029658A1 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs 有权
标题翻译：稳定无菌可过滤脂质体包封的紫杉烷等抗肿瘤药物
公开(公告)号：US20060029658A1
公开(公告)日：2006-02-09
申请号：US11196123
申请日：2005-08-03
申请人： Jia-Ai Zhang , Sydney Ugwu , Lan Ma , Gopal Anyarambhatla , Imran Ahmad
发明人： Jia-Ai Zhang , Sydney Ugwu , Lan Ma , Gopal Anyarambhatla , Imran Ahmad
IPC分类号： A61K9/127 , A61K31/337
CPC分类号： A61K9/127 , A61K9/1272 , A61K9/19 , A61K31/337
摘要： The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.
摘要翻译：本发明提供了包封在脂质体中的一种或多种抗肿瘤药物的制剂，其包括至少除了抗肿瘤药物之外的脂质部分，其中该组合物在室温下在水溶液中是稳定的。

6. 发明申请

US20060030578A1 Pharmaceutically active lipid based formulation of irinotecan 审中-公开
标题翻译：伊立替康的药物活性脂质制剂
公开(公告)号：US20060030578A1
公开(公告)日：2006-02-09
申请号：US11177194
申请日：2005-07-08
申请人： Imran Ahmad , Jia-Ai Zhang
发明人： Imran Ahmad , Jia-Ai Zhang
IPC分类号： A61K31/4745 , A61K9/127
CPC分类号： A61K31/4745 , A61K9/127
摘要： Delivering therapeutic amounts of irinotecan remains limited due to its highly water insoluble properties. This invention overcomes this limitation by presenting a novel method of preparing liposomal irinotecan by first inactivating irinotecan prior to liposome formation and then subsequently activating the irinotecan by lowering the pH of the lipid composition to an acidic pH of less than about 3.5, such as between 1.5-3.0 or about 2.
摘要翻译：提供治疗量的伊立替康由于其高度不溶的性质而仍然受到限制。本发明通过提出一种新的制备脂质体伊立替康的方法，通过首先在脂质体形成之前灭活伊立替康，然后通过将脂质组合物的pH降低到小于约3.5，例如1.5之间的酸性pH，然后活化伊立替康 -3.0或约2。

7. 发明申请

US20050249795A1 Gemcitabine compositions for better drug delivery 审中-公开
标题翻译：用于更好的药物递送的吉西他滨组合物
公开(公告)号：US20050249795A1
公开(公告)日：2005-11-10
申请号：US11062654
申请日：2005-02-22
申请人： Jia-Ai Zhang , Imran Ahmad
发明人： Jia-Ai Zhang , Imran Ahmad
IPC分类号： A61K9/127 , A61K31/66 , A61K31/7068 , A61K31/7072 , A61K45/06
CPC分类号： A61K45/06 , A61K9/127 , A61K9/1272 , A61K31/66 , A61K31/7068 , A61K31/7072 , A61K2300/00
摘要： The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped gemcitabine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds including cardiolipin.
摘要翻译：本发明是用于治疗癌症的新型组合物和方法，特别是用于治疗哺乳动物，特别是人类的癌症。本发明的治疗组合物包括脂质体包埋的吉西他滨，其中脂质体可以含有多种中性或带电荷的脂质体形成化合物，包括心磷脂。

8. 发明授权

US07390502B2 SN-38 lipid complexes and their methods of use 失效
标题翻译： SN-38脂质复合物及其使用方法
公开(公告)号：US07390502B2
公开(公告)日：2008-06-24
申请号：US10424258
申请日：2003-04-28
申请人： Imran Ahmad , Jia-Ai Zhang , Aquilur Rahman
发明人： Imran Ahmad , Jia-Ai Zhang , Aquilur Rahman
IPC分类号： A61K9/127
CPC分类号： A61K9/1272 , A61K47/6911
摘要： The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.
摘要翻译：本发明是用于治疗由细胞增殖引起的疾病的新型组合物和方法，特别是用于治疗哺乳动物，特别是人类的癌症。本发明的治疗组合物包括SN-38脂质复合物，其中复合物可以含有各种中性或带电荷的脂质中的任何一种，并且理想的是心磷脂。该组合物能够将SN-38有效地并入复合物中并能够溶解相对高浓度的SN-38。

9. 发明申请

US20050238706A1 Pharmaceutically active lipid based formulation of SN-38 审中-公开
标题翻译： SN-38的药物活性脂质制剂
公开(公告)号：US20050238706A1
公开(公告)日：2005-10-27
申请号：US11061044
申请日：2005-02-18
申请人： Imran Ahmad , Jia-Ai Zhang
发明人： Imran Ahmad , Jia-Ai Zhang
IPC分类号： A61K9/127 , A61K31/4745 , A61P31/12 , A61P35/00
CPC分类号： A61K9/127 , A61K31/4745
摘要： SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes. The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN38 into complexes and are capable of solubilizing relatively high concentrations of SN38.
摘要翻译： SN38，喜树碱衍生物水溶性差，高亲脂性喜树碱衍生物，对各种人类癌症非常活跃。由于水溶性非常差，SN38不能用于治疗癌症患者，因为不能将足量的溶解在药物制剂中。本发明通过教导用于直接给予人类癌症患者的制剂的新的药学上可接受的SN38脂质体复合物制剂来克服这些限制。所要求保护的发明还描述了制备脂质体SN38复合物和脂质体SN38复合物的抗肿瘤组合物的方法，以允许给予足量的治疗各种类型的癌症和作为抗病毒剂。本发明还涉及可注射的无菌溶液，抗肿瘤组合物，脂质体。本发明是用于治疗由细胞增殖引起的疾病的新型组合物和方法，特别是用于治疗哺乳动物，特别是人类的癌症。本发明的治疗组合物包括SN38脂质复合物，其中复合物可以含有各种中性或带电荷的脂质中的任何一种，并且理想的是含有心磷脂。组合物能够有效地将SN38并入复合物中，并能够溶解相对高浓度的SN38。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式